WO2022269451 - BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVA
National phase entry:
Publication Number
WO/2022/269451
Publication Date
29.12.2022
International Application No.
PCT/IB2022/055690
International Filing Date
20.06.2022
Title **
[English]
BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVA
[French]
ANTICORPS BISPÉCIFIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE L'HIDROSADÉNITE SUPPURÉE
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
BECK, Sabine
Novartis Pharma AG
Postfach
4002 Basel, CH
KIFFE, Michael
Novartis Pharma AG
Postfach
4002 Basel, CH
KOVARIK, Jiri
Novartis Pharma AG
Postfach
4002 Basel, CH
LOESCHE, Christian
Novartis Pharma AG
Postfach
4002 Basel, CH
RODRIGUES, Margarida
Novartis Farma - Produtos Farmacauticos, S.A.
Apartado 150
2741-901 Porto Salvo, PT
STEIN, Richard
Novartis Pharma AG
Postfach
4002 Basel, CH
TANG, Yu
9 Woodchester Drive
Acton, Massachusetts 01720, US
WALDRON-LYNCH, Frank
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
Priority Data
63/213,686
22.06.2021
US
63/223,479
19.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2076 | |
| EPO | Filing, Examination | 9671 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 4160 |
Total: 17109 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of hidradenitis suppurativa in a subject.[French]
L'invention concerne des anticorps monoclonaux bispécifiques bivalents (bbmAb) ou des variants de ceux-ci destinés à être utilisés dans le traitement ou pour le soulagement des symptômes de l'hidrosadénite suppurée chez un sujet.